MGX - Metagenomi Therapeutics, Inc. News

Discover

MGX

Metagenomi Therapeutics, Inc.

1.00

2 x 0.76

2 x 1.34

bid

ask

0.01

0.68%

2 @ 05:53 PM

1.00 +0.00 (0.00%)

Ytd	-38.27%
1y	-68.05%

0.99

day range

1.04

0.98

52 week range

3.35

Open	1.00	Prev Close	0.99	Low	0.99	High	1.04	Mkt Cap	37.78M
Vol	147.18K	Avg Vol	158.27K	EPS	-2.49	P/E	N/A	Forward P/E	-1.38
Beta	0.69	Short Ratio	0.60	Inst. Own	34.68%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-13	50-d Avg	1.16	200-d Avg	1.36	1yr Est	18.40

MGX News

benzinga.com

Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7

Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight an

benzinga.com

Metagenomi Q2 EPS $(0.73) Misses $(0.57) Estimate, Sales $(257.000K) Miss $2.960M Estimate

Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.73) per share which missed the analyst cons

benzinga.com

Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5

Chardan Capital analyst Keay Nakae maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Buy and

benzinga.com

Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9

Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight an

benzinga.com

Metagenomi Q1 EPS $(0.61) Misses $(0.55) Estimate, Sales $1.248M Miss $5.925M Estimate

Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.61) per share which missed the analyst cons

benzinga.com

Metagenomi Reports Study Showing CRISPR Editing Efficiency; Findings Support Development of Delivera

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing compan

benzinga.com

Metagenomi Therapeutics Q4 Earnings Assessment

benzinga.com

Metagenomi Changes Name To Metagenomi Therapeutics

New name reflects the Company's strategic evolution focused on later-stage preclinical assets le

benzinga.com

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce

Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 202

benzinga.com

12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com

Metagenomi Promotes Jian Irish To CEO, Appoints Willard Dere Board Chair

Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizin

benzinga.com

Metagenomi Q3 EPS $(0.55) Beats $(0.60) Estimate, Sales $8.659M Beat $7.400M Estimate

Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.55) per share which beat the analyst consen

benzinga.com

HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Metagenomi (NASDAQ:MGX) with a Buy

benzinga.com

Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $11

Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:MGX) with a Buy and lowers t

benzinga.com

Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $12

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the

benzinga.com

Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With '

OpenAI CEO Sam Altman regrets underestimating Elon Musk's potential abuse of power to block Open

benzinga.com

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a str

benzinga.com

Demystifying Metagenomi: Insights From 4 Analyst Reviews

benzinga.com

Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

benzinga.com

Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $12

Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:MGX) with a Buy and lowers t

benzinga.com

Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $16

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the

benzinga.com

Metagenomi Announced The Presentation Of Three Abstracts At The American Society Of Gene & Cell Ther

Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central ne

benzinga.com

Metagenomi Q1 EPS $(0.68) Misses $(0.58) Estimate, Sales $4.13M Miss $7.96M Estimate

Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.68) per share which missed the analyst cons

benzinga.com

HC Wainwright & Co. Maintains Buy on Metagenomi, Lowers Price Target to $7

HC Wainwright & Co. analyst Mitchell Kapoor maintains Metagenomi (NASDAQ:MGX) with a Buy and

benzinga.com

Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $20

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the

benzinga.com

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com

Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

benzinga.com

Expert Outlook: Metagenomi Through The Eyes Of 4 Analysts

benzinga.com

HC Wainwright & Co. Maintains Buy on Metagenomi, Raises Price Target to $14

HC Wainwright & Co. analyst Mitchell Kapoor maintains Metagenomi (NASDAQ:MGX) with a Buy and

benzinga.com

Reported Earlier, Metagenomi Highlights Durable Preclinical Results For Hemophilia A Gene Therapy At

Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primat

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Metagenomi (NASDAQ:MGX) with a Buy and

benzinga.com

Chardan Capital Maintains Buy on Metagenomi, Maintains $15 Price Target

Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:MGX) with a Buy and maintain